Diabetes drug metformin inhibits multidrug-resistant breast cancer

December 6, 2017, Public Library of Science

The drug metformin, typically prescribed to treat type 2 diabetes, keeps breast cancer cells from developing multiple drug resistance (MDR) and can reverse MDR after it¹s appeared, according to a study published December 6, 2017 in the open-access journal PLOS ONE by Terra Arnason from the University of Saskatchewan, Canada, and colleagues.

Previous studies have shown that metformin has some antiproliferative activity against multiple types of cancer cells. Moreover, clinical meta-analysis studies on cancer patients who already take metformin to treat diabetes have hinted that the drug may boost their survival and prevent the emergence of new tumors.

Arnason and colleagues probed the effect of metformin on the widely studied cell line MCF7. Metformin, they found, had an antiproliferative effect on MCF7, including cells that were resistant to the common chemotherapeutic Doxorubicin. When cells were pretreated with metformin, the development of drug resistance was prevented or delayed. In addition, experiments conducted in both cell cultures and mouse models of aggressive breast cancer revealed that metformin reversed protein markers associated with MDR after its onset.

These findings establish that metformin has the potential to both reverse MDR in cell lines and prevent its onset. Future research will need to extend the timeline of the study to follow for many months and determine if the effect of is permanent or short-lived.

Explore further: Metformin use does not increase prostate cancer survival

More information: Gerald Davies et al, Metformin inhibits the development, and promotes the resensitization, of treatment-resistant breast cancer, PLOS ONE (2017). DOI: 10.1371/journal.pone.0187191

Related Stories

Metformin use does not increase prostate cancer survival

April 11, 2017
(HealthDay)—Metformin use in combination with docetaxel chemotherapy does not significantly improve survival in patients with diabetes and metastatic castration-resistant prostate cancer, according to a study published ...

Prevalence of metformin use 0.7 percent in prediabetes

April 7, 2017
(HealthDay)—For U.S. adults with prediabetes, the prevalence of metformin use is 0.7 percent, according to a study published online April 3 in Diabetes Care.

Metformin therapeutic as post-ischemic conditioning agent

June 29, 2017
(HealthDay)—Metformin has therapeutic potential as a post-ischemic conditioning agent, according to a study published online June 23 in Cardiovascular Therapeutics.

Metformin use linked to less vitamin B12 measurement

February 17, 2017
(HealthDay)—Long-term metformin use is associated with lower serum vitamin B12 concentration, although metformin users are less likely to receive vitamin B12 testing, according to a study published online Feb. 9 in the ...

Common diabetes drug may help treat ovarian cancer

December 3, 2012
A new study suggests that the common diabetes medication metformin may be considered for use in the prevention or treatment of ovarian cancer. Published early online in CANCER, a peer-reviewed journal of the American Cancer ...

Metformin confers anti-tumor immunity by reactivating exhausted CD8T lymphocytes

February 24, 2016
Anti-cancer effect of tumor infiltrating CD8+T lymphocyte (CD8TIL) is suppressed by interaction between immune-checkpoint molecules such as PD-1 and CTLA-4 expressed on CD8TIL and their ligands expressed on cancer cells, ...

Recommended for you

Non-coding DNA reveals a route by which advanced prostate cancer resists treatment

June 15, 2018
Two research teams converge on epigenetic switches that feed treatment-resistant metastatic prostate tumors. This research highlights the value of exploring gene regulation and large-scale structural changes in the cancer ...

Researchers peer inside cells to spy on cancer's on-off switch

June 15, 2018
Forty years after researchers first discovered it in fruit flies, a once-obscure cluster of proteins called PRC2 has become a key target for new cancer-fighting drugs, due to its tendency—when mutated—to bind to and silence ...

PIM-2 protein kinase regulates T-cell activity differently than PIM-1 or PIM-3 isoform

June 15, 2018
The PIM-2 protein kinase negatively regulates T cell responses in transplantation and tumor immunity, while PIM-1 and PIM-3 are positive regulators, report Medical University of South Carolina (MUSC) investigators in an article ...

Gene testing could identify men with prostate cancer who may benefit from immunotherapy

June 14, 2018
Scientists have identified a pattern of genetic changes that could pick out men with advanced prostate cancer who are likely to benefit from immunotherapy.

Without 'yoga and chardonnay' leukemia stem cells are stressed to death

June 14, 2018
Change is stressful. The change that a healthy blood stem cell undergoes to become a leukemia stem cell (LSC) is no exception—think of healthy blood stem cells as young professionals and the transformation into an LSC as ...

Statins found to enhance efficacy of chemotherapy drug in blood cancers

June 14, 2018
A team of researchers with members affiliated with several institutions in the U.S. has found that some statins could enhance the efficacy of a chemotherapy drug used to fight blood cancers in mouse models. In their paper ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.